8-K: SBC Medical Group Holdings Completes Merger, Set to Begin Trading on Nasdaq

SBC Medical Group Holdings has finalized its merger with Pono Capital Two and will commence trading on the Nasdaq under the ticker symbol SBC on September 18, 2024.

Summary

• SBC Medical Group Holdings has completed its business combination with Pono Capital Two, and will begin trading on the Nasdaq on September 18, 2024.
• The combined company will trade under the ticker symbol SBC for common stock and SBCWW for warrants.
• The merger is expected to provide SBC Medical with access to capital, accelerate business alliances, and facilitate expansion in the US and Southeast Asia.
• SBC Medical provides management services to 164 franchisee treatment centers in Japan, one in Vietnam, and one in California.
• The company's revenue for the six months ended June 30, 2024 was $107.9 million, with a net income of $37.2 million.
• The company's cash flow from operations for the six months ended June 30, 2024 was $22.9 million.
• The company's retained earnings as of June 30, 2024 were $180.1 million.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong financial results, a clear growth strategy, and a successful merger. The company's focus on high-growth markets and its experienced management team are also positive indicators. However, there are some risks associated with the company's expansion plans and the need for additional capital.

Positives

• The merger provides access to new capital and accelerates business alliance opportunities.
• SBC Medical has a scalable business model with a history of profitability.
• The company is focused on high-growth markets in the US and Southeast Asia.
• The company has a long-tenured management team with deep experience in the medical service market.
• SBC Medical anticipates significant organic growth opportunities in sales of high-quality beauty treatment products and from the expansion of research and development of new medical technologies and equipment.

Risks

• The company may need to raise additional capital to execute its business plans.
• There is a risk that the proposed business combination disrupts the current plans of SBC Medical.
• There is a risk that the parties may not recognize the benefits of the Business Combination.
• There is a lack of useful financial information for an accurate estimate of future capital expenditures and future revenue.
• There are risks related to the uncertainty of the projected financial information with respect to SBC.
• There are risks related to SBCs limited operating history, the roll-out of SBCs business and the timing of expected business milestones.
• There are risks related to SBCs ability to implement its business plan and scale its business, which includes the extent of market reception to cosmetic treatment centers, navigating a new and evolving regulatory environment for cosmetic treatment centers, timely fulfillment of product orders, the ability to own, operate and manage safe, high-quality and cost-effective cosmetic treatment centers on an ongoing basis, the performance of our cosmetic treatment centers relative to customer expectations and customers interest in and demand for cosmetic treatment solutions, and building a well-recognized and respected brand.
• There are risks related to SBCs potential profit margin from sales associated with cosmetic treatment centers.
• There are risks related to SBCs ability to formulate, implement and modify as necessary effective sales, marketing, and strategic initiatives to drive revenue growth.
• There are risks related to SBCs ability to expand internationally.
• There are risks related to the viability of SBCs intellectual property and intellectual property created in the future.
• There are risks related to acceptance by the marketplace of the products that SBC markets.
• There are risks related to government regulations and SBCs ability to obtain applicable regulatory approvals and comply with government regulations, including under the rules and regulations of the U.S. Department of Transportation and Federal Aviation Administration, and the risk that SBC may not be able to develop and maintain effective internal controls.

Future Outlook

The Business Combination is expected to provide SBC Medical with improved access to sources of new capital, accelerate business alliance opportunities, facilitate the expansion of its clinic operation support business in the United States and Southeast Asia, and expand its franchise clinic network in Japan and overseas.

Management Comments

• Yoshiyuki Aikawa, CEO of SBC Medical, said: 'We are focused on providing premium care and value to our customers and their patients through transformative treatments and technologies that empower people to positively change their lives and meet new challenges under our Group Purpose.'
• Yoshiyuki Aikawa, CEO of SBC Medical, said: 'Through medical innovation, we aim to contribute to improving the well-being of people where we operate.'
• Yoshiyuki Aikawa, CEO of SBC Medical, said: 'I am confident that our listing on Nasdaq can contribute to our further growth and allow us to offer our advanced consulting services to clinic networks, not only in Japan but other locations internationally, while maintaining our high standards of Japan Quality.'
• Darryl Nakamoto, CEO of Pono Capital Two, said: 'We appreciate the effort and commitment of all the parties involved in this business combination. The listing of SBC Medical on Nasdaq through a business combination with Pono Capital Two is both a milestone for SBC Medical and a step toward international growth for the Company.'
• Darryl Nakamoto, CEO of Pono Capital Two, said: 'Our belief has been that a promising Japan-based company, together with a U.S.-listed company, will help to unlock value for all our shareholders.'

Industry Context

The announcement reflects a trend of international companies seeking access to US capital markets through mergers with special purpose acquisition companies (SPACs). The focus on aesthetic medicine and related services aligns with the growing global demand for such treatments.

Comparison to Industry Standards

• SBC Medical's business model, which combines management services with a franchise network, is similar to other large medical service providers, but its focus on cosmetic treatment centers and its strong presence in Japan differentiate it.
• The company's revenue growth of 28.6% for the six months ended June 30, 2024, is strong compared to the average growth rate of the global aesthetic medical market, which is estimated to be around 10-15% annually.
• The company's EBITDA margin of 20% for FY2023 is competitive with other established players in the medical service industry.
• The company's focus on a multi-brand strategy, including the addition of Rize Clinic and Gorilla Clinic, is a common approach for companies seeking to expand their market reach and cater to different customer segments.
• The company's emphasis on a digitized integrated system and structured educational programs for staff is a key differentiator in the competitive aesthetic medical market.

Management Changes

Corporate Governance

Legal Proceedings

• To the knowledge of SBCs management, there are no legal proceedings pending against SBC.

Related Party Transactions

• The document details numerous related party transactions, including revenue, accounts receivable, finance lease receivables, long-term investments, advances from customers, notes payable, and due to/from related party balances.
• These transactions involve various entities controlled by or related to the CEO of the Company, including Medical Corporations, and other entities.
• The Company made a prepayment of JPY2.4 billion (approximately $18.32 million when payment was made) in December 2022 to purchase a patent use right ready to be used on January 1, 2023 with the useful life of sixteen years from SBC Tokyo Medical University, previously known as Ryotokuji University.
• In February 2023, the Company paid off the retirement compensation expense of $22,082,643 accrued to Yoshiko Aikawa.
• In August 2023, the Company entered into property sales agreements with General Incorporation Association SBC, an entity under common control of the Company, to sell its certain properties and entire equity interest in Ai Inc. and Lange Inc., with a total amount of JPY3,113,603,355 (approximately $22,473,000 when received), excluding JPY232,177,630 consumption tax.
• In January 2024, the Company acquired 353,600 shares of common stock of Waqoo, a related-party company listed on the Tokyo Stock Exchange, with a fair value of $5,565,938 through a share exchange agreement.

Stakeholder Impact

• Shareholders of Pono Capital Two received common stock of SBC Medical Group Holdings Incorporated.
• Holders of Pono warrants received warrants of SBC Medical Group Holdings Incorporated with substantively identical terms.
• SBC Medical's listing on Nasdaq is expected to enhance its brand and attract top talent.
• The merger is expected to provide SBC Medical with improved access to capital, which will support its growth plans.
• The company's focus on providing premium care and value to customers and their patients is expected to benefit both groups.
• The company's expansion plans are expected to create new job opportunities.

Next Steps

• SBC Medical will begin trading on the Nasdaq on September 18, 2024.
• The company plans to expand its clinic operation support business in the United States and Southeast Asia.
• The company plans to expand its franchise clinic network in Japan and overseas.
• The company plans to strengthen its ability to meet the inbound demand in Japan.
• The company plans to expand its research and development of new medical technologies and equipment.
• The company plans to compete in areas of regenerative medicine and anti-aging.

Key Dates

Keywords

cosmetic treatment centers, aesthetic medicine, franchise clinics, medical services, management services, Nasdaq, merger, Japan, Southeast Asia, beauty treatment products